Sean F. Moran - 24 Oct 2025 Form 4 Insider Report for Corbus Pharmaceuticals Holdings, Inc. (CRBP)

Role
Chief Financial Officer
Signature
/s/Sean Moran
Issuer symbol
CRBP
Transactions as of
24 Oct 2025
Net transactions value
-$165,638
Form type
4
Filing time
27 Oct 2025, 16:22:21 UTC
Previous filing
18 Feb 2025
Next filing
16 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Moran Sean F. Chief Financial Officer C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 500 RIVER RIDGE DRIVE, NORWOOD /s/Sean Moran 27 Oct 2025 0001451495

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CRBP Common Stock, par value $0.0001 per share Options Exercise $55,299 +12,981 +18% $4.26 86,294 24 Oct 2025 Direct F1
transaction CRBP Common Stock, par value $0.0001 per share Sale $220,937 -12,981 -15% $17.02 73,313 24 Oct 2025 Direct F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CRBP Stock options (right to buy) Options Exercise $0 -12,981 -56% $0.000000 10,386 24 Oct 2025 Common Stock 12,981 $4.26 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This amount includes 57,632 unvested RSUs subject to each grant's vesting schedule as previously reported.
F2 This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2025.
F3 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.79 to $17.38. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The annual option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. 25% of the option vested on February 13, 2024, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on March 13, 2024.